High Immune Response From Covishield & Covaxin: Study
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
A ‘real-world’ study of vaccinated healthcare workers has found Covishield and Covaxin could produce a high immune response in up to 95% recipients and prevent serious disease in those infected after immunisation. Interestingly, the Oxford vaccine Covishield could generate antibodies in more individuals compared to Bharat Biotech’s Covaxin, a pre-print of the first such Indian study has stated. Most vaccine efficacy studies so far have been lab-based.

The pan-India study of 515 vaccinated healthcare workers — 425 with Covishield and 90 with Covaxin — from 13 states and 22 cities found the vaccines could generate an immune response in 95% recipients 21-36 days after the second dose. Seropositivity was observed in 98% of those immunised with Covishield as opposed to 80% Covaxin recipients, a finding the researchers called surprising.

Even the anti-spike antibody titre was found to be significantly higher in Covishield recipients (115 AU/ml) compared to Covaxin (51 AU/ml). While factors such as gender, BMI and other comorbidities didn’t seem to play much of a role, the seropositivity rate or antibodies in people above 60 years or those with type 2 diabetes was found to be significantly lower. Seropositivity rate was significantly more in participants with age less than 60 years as against 87.2% in the 60-plus bracket. Infection post vaccination was seen in 5% of the study group, but none suffered from severe Covid-19.

Lead author and endocrinologist Dr Awadhesh Kumar Singh of G D Hospital & Diabetes Institute, Kolkata, said the study was not to comment on which one is a better vaccine, but to look at the real-world effectiveness of vaccination. “In the absence of measuring neutralising antibody and cell mediated response, it is difficult to comment whether one is superior,” he said. Results of the Cross-sectional Coronavirus Vaccine-induced Antibody Titre (COVAT) study were published in pre-print server MedRxiv on June 4.

“In individuals who have had Covid infection, both vaccines are equally good and could produce high antibodies even after a single shot. But for those who haven’t got Covid, Covishield could provide an edge,” he said.

Source:
https://www.medrxiv.org/content/10.1101/2021.06.02.21258242v1
Dr. S●●●●●●A R●Y and 8 others like this19 shares
Like
Comment
Share
S●i p●●●a
S●i p●●●a General Medicine
Will crp elevate after covid vaccination?
Jun 7, 2021Like